Introduction
Glioblastoma is the most common primary brain tumor, a highly aggressive malignancy, which is considered one of the most lethal cancers (Gurney and Kadan-Lottick, 2001 ). Despite aggressive approaches, treatment of glioblastoma patients represents an ongoing challenge, as complete surgical resection of the tumor is difficult and glioblastoma are refractory to most current chemotherapy regimens.
The transcription factor nuclear factor-kappaB (NFkB) has been connected to many aspects of tumor formation and progression, including inhibition of apoptosis by increasing the expression of survival factors (Karin et al., 2002) . NF-kB is composed of hetero-or homodimers of the NF-kB/Rel family of proteins (Karin et al., 2002) . In most cell types, NF-kB proteins are sequestered in the cytoplasm by their interaction with inhibitor of kB (IkB) proteins, predominantly IkB-a, and therefore remain inactive (Karin et al., 2002) . NF-kB activity is induced in response to a variety of stimuli, for example inflammatory cytokines, cellular stress, reactive oxygen species or anticancer agents. Most stimuli cause activation of kinases in the IkB kinase (IKK) complex, which phosphorylate IkB proteins, thereby initiating their degradation via the proteasome (canonical pathway). NF-kB complexes are in turn freed to translocate to the nucleus, where they interact with specific DNA-binding sites and regulate the transcription of target genes (Hayden and Ghosh, 2004) . NF-kB target genes include various antiapoptotic proteins (Karin et al., 2002) . Constitutive NF-kB activation has been described in various cancers of hematopoietic and epithelial origin, for example Hodgkin's lymphoma, breast cancer, lung cancer, melanoma and pancreatic cancer, where it has been implicated in conferring chemoresistance (Wang et al., 1999; Biswas et al., 2000; Huang et al., 2000; Hinz et al., 2001; Jiang et al., 2001) . Inhibition of NF-kB signaling, for example by overexpression of non-degradable IkBa mutants (IkBa superrepressor) or by proteasome inhibitors that prevent IkBa degradation, has been reported to sensitize tumor cells to apoptosis induced by TNFa or anticancer agents (Jeremias and Debatin, 1998; Karin et al., 2004) .
Increased constitutive NF-kB activity has been reported in glioblastoma tissue specimens, but not in normal cerebral tissue (Hayashi et al., 2001; Nagai et al., 2002; Wang et al., 2004) , suggesting that NF-kB may also be a potential therapeutic target in glioblastoma. However, whether these basal levels of NF-kB activity contribute to primary resistance of glioblastoma is not known. Also, the impact of NF-kB on inducible chemoresistance of glioblastoma cells in response to cytotoxic stimuli that trigger NF-kB as part of a cellular stress response has not been investigated in detail. In search for novel strategies to target apoptosis resistance of glioblastoma, we investigated the role of constitutive and drug-induced NF-kB activity in regulating apoptosis of glioblastoma cells.
Results
Constitutive NF-kB DNA-binding activity in glioblastoma cell lines To gain insight into the role of NF-kB in glioblastoma, we first investigated whether constitutive NF-kB activity was detectable in glioblastoma cell lines. To address this question, a panel of eight different glioblastoma cell lines -U87MG, T98G, U118MG, U138MG, U373MG, A172, LN-18 and LN-229 -was analysed for NF-kB DNA-binding activity. Nuclear extracts of cells serumstarved for 24 h, untreated or stimulated with the known NF-kB stimulator Tumor Necrosis Factor a (TNFa), used as positive control, were assayed by electrophoretic mobility shift assay (EMSA). Among the cell lines screened, T98G and LN-229 showed a moderate constitutive NF-kB DNA-binding activity, whereas the other six exhibited low constitutive activity when compared to the TNFa-induced NF-kB DNA binding ( Figure 1a) . Also, constitutive NF-kB activity was relatively low in glioblastoma cells compared to KM-H2 Hodgkin/Reed-Sternberg (HRS) cells that have been described as prototypic tumor with high constitutive NF-kB activity (Figure 1b) . For further investigation, we selected U87MG as a prototypic glioblastoma cell line with low constitutive NF-kB activity and T98G as prototypic glioblastoma cell line with moderate basal NF-kB activity.
Doxorubicin and TRAIL-induced NF-kB DNA-binding activity To explore the role of NF-kB in chemoresistance of glioblastoma, we selected two prototypic stimuli, known to trigger NF-kB activation via distinct pathways: the genotoxic agent doxorubicin and the death-inducing ligand TNF-related apoptosis inducing ligand (TRAIL). Doxorubicin was chosen in pilot experiments from a host of genotoxic drugs, as it proved to be a potent NF-kB activator in glioblastoma cells (data not shown). Kinetic analysis revealed that doxorubicin markedly induced NF-kB DNA-binding activity within 2-6 h in glioblastoma cells (Figure 2a) . Incubation of nuclear extracts with specific antibodies against the p50, p65 and c-Rel subunits of NF-kB showed that the induced complex comprised the p50 and p65 proteins (Figure 2b ), usually regarded as main components of the antiapoptotic NF-kB complex (Karin et al., 2002) .
Next, NF-kB activation in response to TRAIL, a prototypic death-inducing ligand, was investigated. Stimulation with TRAIL increased NF-kB DNA-binding activity over the untreated control in both U87MG and T98G glioblastoma cells (Figure 2c ). These results demonstrate that the DNA-damaging agent doxorubicin and the death-inducing ligand TRAIL activate NF-kB in glioblastoma cells.
IkBa degradation by doxorubicin and TRAIL
To examine whether NF-kB activation by doxorubicin or TRAIL occurs via the canonical pathway, which involves IkBa degradation, IkBa protein levels were assayed by Western blot analysis. IkBa degradation was detected in U87MG and T98G cells after 6 and 12 h of doxorubicin treatment (Figure 3a) , whereas a decrease in IkBa protein levels was already detectable after 1 h incubation with TRAIL in both cell lines (Figure 3b ). TNFa stimulation, used as positive control, induced a rapid IkBa degradation within 15 min incubation, with protein levels increasing again after 1 h (Figure 3c ). These results demonstrate that NF-kB activation induced by doxorubicin or TRAIL involved IkBa degradation, indicating that NF-kB was activated via the canonical pathway.
Doxorubicin-induced nuclear translocation of NF-kB and transcriptional activation Next, we wished to confirm that NF-kB complexes triggered by doxorubicin or TRAIL were transcriptionally a b − − −
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Free probe active. To this end, translocation of the p65 subunit from the cytoplasm into the nucleus upon doxorubicin treatment was assessed by immunofluorescence ( Figure 4a and b). After 4 h incubation, some nuclei were positive for p65, but most of the proteins were still cytosolic; after 6 h p65 was clearly detectable in the majority of the nuclei. TNFa was used as positive control for nuclear translocation of p65 ( Figure 4a and b, second column). To verify transcriptional activity of the nuclear NF-kB complexes, reporter assays were performed using a construct containing three NF-kB sites upstream of the luciferase gene. Doxorubicin induced an approximately ninefold increase in luciferase activity in U87MG cells and a fourfold increase in T98G cells after 24 h incubation ( Figure 4c ). Taken together, these results indicate that doxorubicin-induced NF-kB complexes are transcriptionally active in glioblastoma cells.
No sensitization for cytotoxic drug-or TRAIL-induced apoptosis by specific NF-kB inhibition Having established that both TRAIL and doxorubicin induced NF-kB activity, we next investigated whether (b) Specificity of NF-kB complexes was shown by supershift experiments. U87MG were left untreated or treated for 4 h with 1 mg/ml, T98G cells were left untreated or treated with 3 mg/ml doxorubicin. Nuclear extracts of doxorubicin-treated cells were subjected to EMSA without or with preincubation with specific antibodies against p50, p65 or c-Rel. (c) U87MG or T98G cells were left untreated (À) or treated with 10 ng/ml (U87MG) or 2.5 ng/ml (T98G) TRAIL for the indicated times. Nuclear extracts were analysed by EMSA.
this activation contributes to glioblastoma cell death. To specifically inhibit NF-kB, we engineered glioblastoma cells that transiently expressed an IkBa-SR mutant, which cannot be phosphorylated and thus is resistant to proteasomal degradation. Adenoviral transduction of U87MG and T98G cells led to a strong expression of IkBa-SR, both in control cells and in cells treated with TNFa, TRAIL or doxorubicin ( Figure 5a ). NF-kB inhibition had no impact on spontaneous apoptosis of glioblastoma cells (Figure 5b -e). Also, NF-kB inhibition did not significantly alter sensitivity of U87MG and T98G cells to doxorubicin-or TRAIL-induced apoptosis in U87MG and T98G cells (Figure 5b -e). Moreover, we extended our studies to additional chemotherapeutic agents and to stable inhibition of NF-kB. Similarly, stable inhibition of NF-kB by retrovirally expressed IkBa-SR did not alter the sensitivity of U87MG or T98G glioblastoma cells towards temozolomide (TMZ)-, carmustine BCNU-or etoposide (VP16)-induced apoptosis ( Figure 6 ).
NF-kB-independent sensitization for TRAIL-induced apoptosis by proteasomal inhibition Proteasomal inhibition is often described as a surrogate method for NF-kB inhibition without taking into account the effects on other, NF-kB-independent proteins. Thus, we compared the effects of specific NF-kB inhibition to those of the proteasome inhibitor MG132. Control experiments showed that preincubation with MG132 before doxorubicin or TRAIL treatment led to a marked decrease of NF-kB DNA binding in U87MG and T98G cells ( To discriminate whether the observed reduction in viability was due to increased cell death and/or reduced proliferation, apoptosis was measured under the same experimental conditions. As seen in the viability assays, proteasome inhibition by MG132 did not sensitize U87MG and T98G cells to doxorubicin-induced apoptosis ( Figure 9a and b), whereas combined treatment of MG132 and TRAIL increased TRAIL-induced apoptosis (Figure 9c and d) . Activation of the apoptotic pathway upon combined treatment of MG132 and TRAIL was confirmed by using the universal caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (zVAD.fmk), which completely abolished apoptosis Cells were left untreated (À) or treated with 1 mg/ml (U87MG) or 3 mg/ml (T98G) doxorubicin, with 10 ng/ml (U87MG) or 2.5 ng/ml (T98G) TRAIL and with 50 ng/ml TNFa as positive control each for indicated times. Expression of a -tubulin was used as loading control. In (a) to (c) a representative result of three independent experiments is shown.
Role of NF-jB in apoptosis of glioblastoma K La Ferla-Brühl et al induced by TRAIL and MG132 in both cell lines (Figure 9e and f). Also, nuclear morphology of cells treated with TRAIL and MG132 exhibited typical apoptotic features, for example condensed and fragmented nuclei (Supplementary Figure 1a and b) . We also controlled that doxorubicin efficiently induced DNA damage under the chosen experimental conditions by detection of phospho-histone H2A.X foci (Supplementary Figure 1c and d), an indirect readout for DNA damage/repair (Paull et al., 2000) . Together, these results indicate that proteasome inhibition sensitizes glioblastoma cells for TRAIL-but not for doxorubicininduced loss of viability and apoptosis independent of NF-kB.
Discussion
As NF-kB has been reported to play an important role in regulation of apoptosis and chemoresistance in cancer (Darnell, 2002) , there has been an increasing interest in the NF-kB pathway as a potential target for cancer therapy. The antiapoptotic function of NF-kB has been well established in several cancers of the epithelial or hematopoietic lineage. However, its impact in modulating apoptosis in malignant glioma remains elusive. Therefore, the first aim of our study was to clarify whether constitutive NF-kB activation is a feature of glioblastoma and contributes to the regulation of spontaneous apoptosis. Our findings, showing that constitutive NF-kB DNA binding activity in different glioblastoma cell lines was low or moderate compared to a Hodgkin's cell line, a prototypic tumor with high basal NF-kB activity (Mathas et al., 2002) , do not support the idea that constitutive NF-kB activity is a general feature of glioblastoma. The NF-kB pathway was principally intact in glioblastoma cells, as NF-kB was strongly activated by the potent NF-kB activator TNFa. Inhibition of NF-kB by overexpression of IkBa superrepressor did not significantly influence spontaneous apoptosis of glioblastoma cells. As NF-kB inhibition has been U87MG and T98G cells were left untreated or treated with 50 ng/ml TNFa for 2 h and 1 mg/ml (U87MG) or 3 mg/ml (T98G) doxorubicin for 4 and 6 h. NF-kB translocation was visualized by fluorescence microscopy using an antibody raised against p65 in combination with a secondary FITC-labeled antibody. The white arrowheads indicate nuclear staining. Scale bar: 40 mm. (c) Transcriptional activity of doxorubicin-induced NF-kB in U87MG and T98G cells was examined by dual luciferase assays, as described in Material and methods. Cells were left untreated (À) or treated ( þ ) with 1 mg/ml (U87MG) or 3 mg/ml (T98G) doxorubicin for 24 h. Normalized fold luciferase induction is shown in mean values þ s.d. of three independent triplicate experiments. Statistical analysis was performed by the Student's t-test, *Po0.005.
Role of NF-jB in apoptosis of glioblastoma K La Ferla-Brühl et al reported to trigger massive spontaneous apoptosis in Hodgkin's lymphoma (Hinz et al., 2001) , these findings point to a differential role of NF-kB in regulating cell survival and apoptosis in glioblastoma compared to other cancers, for example of the hematopoetic system such as Hodgkin's lymphoma. In addition to regulate cell survival and death under steady-state conditions in the absence of an external stimulus, NF-kB has also been implied to mediate chemoresistance, that is in response to cytotoxic stimuli. To explore the impact of NF-kB on inducible chemoresistance of glioblastoma, we used two prototypic classes of cytotoxic stimuli, known to trigger NF-kB activation via distinct pathways: chemotherapeutic agents and death-inducing ligands such as TRAIL. However, specific inhibition of NF-kB by overexpression of IkBa superrepressor did not significantly enhance apoptosis induced by different anticancer drugs, for example doxorubicin, etoposide, TMZ and BCNU, or by TRAIL. Similarly, inhibition of NF-kB by ectopic expression of the IkBa superrepressor has previously been reported to have no influence on CD95 ligand or TRAIL-induced apoptosis in glioblastoma cells (Hermisson and Weller, 2003) or on sensitivity towards daunorubicin in adenocarcinoma cells, breast cancer cells or lymphoid cells (Bentires-Alj et al., 1999) . In contrast, inhibition of NF-kB increased cell death upon treatment with BCNU, carboplatin, TNFa or SN38 in glioblastoma cells (Weaver et al., 2003) (a) U87MG and T98G cells were transduced with a control adenoviral vector (Ad-control) or the IkBa -SR vector (Ad-IkBSR), left untreated or treated with 50 ng/ml TNFa (T), 10 ng/ml (U87MG) or 2.5 ng/ml (T89G) TRAIL (TR) for 1 h or with 1 mg/ml (U87MG) or 3 mg/ml (T89G) doxorubicin (D) for 4 h. Lysates were assayed for IkBa expression by Western blot analysis; a-tubulin served as loading control. (b, c) After transduction, U87MG or T98G control cells (white bars) and IkBa-SR-expressing cells (black bars) were left untreated (À) or treated ( þ ) for 48 h with 1 mg/ml (U87MG) or 3 mg/ml (T98G) doxorubicin. Apoptosis was assessed by Annexin V staining and FACS analysis. (d, e) Transduced U87MG or T98G control cells (white bars) and IkBa-SR-expressing cells (black bars) were stimulated with TRAIL for 24 h as indicated. Apoptosis was measured by FACS analysis of DNA fragmentation in propidium iodide-stained nuclei.
Role of NF-jB in apoptosis of glioblastoma K La Ferla-Brühl et al 1996). These findings suggest that the effect of NF-kB inhibition may depend on the specific drug and/or cell type used. Similar to overexpression of the IkBa superrepressor, inhibition of NF-kB by the proteasome inhibitor MG132 did not increase the sensitivity of glioblastoma cells towards doxorubicin, although it prevented doxorubicin-induced DNA binding of NF-kB complexes, indicating that chemical inhibition of NF-kB was not able to improve the efficacy of doxorubicin-based regimens. Interestingly, proteasome inhibition significantly enhanced TRAIL-induced loss of viability and apoptosis in contrast to doxorubicin. Cell death by apoptosis upon combined treatment with TRAIL and MG132 was confirmed by characteristic biochemical hallmarks of apoptosis, for example condensed and fragmented nuclei, and also by its dependence on caspase activity.
Proteasome inhibitors have previously been reported to enhance TRAIL-induced apoptosis in a variety of cancers, for example glioblastoma (Kasuga et al., 2004; Kim et al., 2004; Yin et al., 2005) and prostate, colon or bladder cancer (Johnson et al., 2003) , as well as primary kerationocytes (Leverkus et al., 2003) . Although some potential mediators of this sensitization effect have been indicated, for example p21 (Lashinger et al., 2005) , c-FLIP (Sayers et al., 2003) , Bik and Bim (Nikrad et al., 2005) , whereas others have been excluded, for instance Bcl-2 (Nencioni et al., 2005) , Bax (He et al., 2004) and Bcl-xL (Johnson et al., 2003) , the specific contribution of NF-kB to this phenomenon remained unclear. In fact, there is only one other report pointing to a differential role of proteasome versus NF-kB inhibition in the regulation of TRAIL-induced apoptosis in glioblastoma cells, possibly by blocking degradation of active caspases (Kim et al., 2004) . Together, these Role of NF-jB in apoptosis of glioblastoma K La Ferla-Brühl et al findings suggest that the enhancement of TRAILinduced apoptosis by proteasome inhibition occurs in an NF-kB-independent manner, involving proteasomedependent proteins other than NF-kB. However, the exact mechanism(s) underlying the proteasome-induced sensitization for TRAIL-induced apoptosis in glioblastoma are subject to further investigation. Another important consideration is that, under some circumstances, NF-kB activation may even contribute to cytotoxic activity of drugs. We previously reported that inhibition of NF-kB reduced betulinic acid-induced apoptosis in neuroblastoma cell lines (Kasperczyk et al., 2005) . Also, Campbell et al. (2004) showed that NF-kB mediates daunorubicin-or UV-induced apoptosis through active repression of antiapoptotic gene expression by the NF-kB subunit p65. Thus, the characteristic antiapoptotic and growth-promoting function of NF-kB reported for many cancers cannot be generalized to all tumors and inhibition of NF-kB for therapeutical purposes may even be counterproductive for certain stimuli and/or types of cancer.
By demonstrating that specific inhibition of NF-kB had no impact on apoptosis in response to two prototypic classes of apoptotic stimuli with distinct modes of action, that is, chemotherapeutic drugs or death-inducing ligands, our findings indicate that the proposed benefits of NF-kB inhibitors for chemosensitization of cancers cannot be taken for granted and depend on the specific context. In contrast to selective NF-kB inhibitors, proteasome inhibitors, which increased TRAIL-induced apoptosis in an NF-kB-independent manner, may provide a novel strategy to enhance the efficacy of TRAIL-based regimens. Thus, proteasome inhibitors may open new perspectives for the treatment of glioblastoma, which warrants further investigation.
Materials and methods

Cell culture
The human malignant glioma cell lines U87MG, T98G, U118MG, U138MG, U373MG, A172, LN-18 and LN-229 used for this study were obtained from ATCC (Manassas, VA, USA). KM-H2 Hodgkin's lymphoma cells were kindly provided by S Mathas from the Max Delbrueck Center for Molecular Medicine (Berlin, Germany). U87MG and T98G cells were grown in Dulbecco's modified Eagle's medium (Invitrogen Corporation, Karlsruhe, Germany), whereas all other cells were cultured in RPMI 1640 medium (Invitrogen Corporation). Media were supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin (both Invitrogen Corporation) and 10% fetal calf serum (FCS) (Biochrom AG, Berlin, Germany).
Chemicals
Recombinant human TNFa was purchased from Biochrom, doxorubicin, etoposide and BCNU from Sigma (SigmaAldrich, Taufkirchen, Germany), recombinant human TRAIL from R&D Systems (Wiesbaden, Germany), the proteasome inhibitior MG132 from Calbiochem (Merck Biosciences GmbH, Bad Soden, Germany), the broad-spectrum inhibitor of caspases zVAD.fmk from Bachem (Bubendorf, Switzerland) and TMZ was a kind gift of Schering-Plough. All stimulations were performed under serum-free conditions.
Nuclear protein extraction and EMSA Nuclear extracts were prepared according to established procedures (Andrews and Faller, 1991) with minor modifications (Kasperczyk et al., 2005) . In brief, after appropriate incubation, cells were washed, scraped and collected by centrifugation at 1000 g for 5 min at 41C. Cells were resuspended in buffer A, allowed to swell on ice for 10 min, a 10% Igepal CA-630 (Sigma-Aldrich) solution was added and after vortexing the cell suspensions were centrifuged again. The remaining nuclear pellets were resuspended in buffer B and incubated on ice for 20 min on a shaking platform. Nuclear supernatants were obtained by centrifugation at 16000 g at 41C for 10 min. Protein concentrations were determined by the Bradford method (Bradford, 1976) . The following sequence was used as specific labeled oligomer for NF-kB: 5 0 -AGTT GAGGGGACTTTCCCAGGC-3 0 (sense). Single-stranded oligonucleotides were labeled with g-[ 32 P]-ATP by T4-polynucleotide kinase (MBI Fermentas GmbH, St Leon-Rot, Germany), annealed to the complementary oligomer strand and purified on sephadex columns (Micro Bio-Spin P30, Biorad Laboratories, Munich, Germany). Binding reactions, containing 5 mg nuclear extract, 1 mg Poly(dI:dC), 2 pmol labeled oligonucleotide (15 000 cpm) and 5 Â binding buffer were incubated for 30 min on ice. Binding complexes were resolved by electrophoresis in non-denaturing 6% polyacrylamide gels using 0.3 Â TBE as running buffer and assessed by autoradiography. The following antibodies were used for supershift (1 mM-U87MG, 3 mM-T98G) and treated for 4 h with 1 mg/ml (U87MG) or 3 mg/ml (T98G) doxorubicin or 10 ng/ml (U87MG) or 5 ng/ml (T98G) TRAIL, in the presence or absence of MG132. Nuclear extracts were analysed by EMSA.
experiments: p-50 (sc-7178X), p-65 (sc-372X), cRel (sc-70X), all from Santa Cruz (Santa Cruz, Biotechnology Inc., Heidelberg, Germany). Representative EMSAs are shown.
Luciferase assay 2 Â 10 5 cells were seeded in six-well plates 24 h before transfection. Cells were transiently transfected with 1 mg of a 3 Â kB-firefly plasmid, and 0.02 mg of a luciferase renilla vector under the control of the ubiquitin promoter (Baumann et al., 2002) . Transfection was carried out by Lipofectamine (Invitrogen Corporation) in serum-free medium, according to the manufacturer's instructions. After 6 h incubation with the DNA-lipofectamine complexes, 1 ml medium supplemented with 10% FCS was added and cells were allowed to grow overnight. After washing and renewing medium, cells were stimulated appropriately. Luciferase activity was determined 24 h after transfection using a Berthold luminometer (Bad Wildbad, Germany) . Values for firefly luciferase activity were normalized to renilla activity.
Adenoviral transduction
Cells were transduced with a replication-defective adenovirus, either containing a CMV promoter/enhancer IkBa (S32/36A) expression cassette or, for control, a LacZ gene instead of IkBa (S32/36A) (Zwacka et al., 2000) . Adenoviral infection was performed in a medium containing 2% FCS for 24 h, after which cells were harvested for transgenic analysis by Western blot or further treatment with doxorubicin or TRAIL.
A multiplicity of infection of 5000 particles/cell was used.
Production of retrovirus and retroviral transduction
The pCFG5-IEGZ retroviral vector system, as described by Denk et al. (2001) , was used to infect U87MG and T98G glioblastoma cells. PT67 producer cells (Clontech, Palo Alto, CA, USA) were transfected with empty pCFG5-IEGZ vectors or pCFG5-IEGZ vectors containing IkB-a-(S32; 36A) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendation. Twenty-four hours after transfection, PT67 producer cells were selected for 3 weeks with 0.25 mg/ml Zeocin (Invivogen, San Diego, CA, USA). U87MG and T98G cells were seeded 24 h before infection in six-well plates at a density of 1 Â 10 5 cells/well. To produce virus-containing supernatants, PT67 producer cells were cultivated for 24 h in a medium without zeocin. At the day of infection, the PT67 cell supernatant was obtained, filtered through a 0.45-mm filter and 8-mg/ml of polybrene (c, d) U87MG and T98G cells were left untreated or treated with 0.5-10 ng/ml TRAIL alone (white bars) or in combination with 3 mM MG132 after 4 h of pretreatment with MG132 (black bars) for 24 h. Apoptosis was measured by FACS analysis of DNA fragmentation in propidium iodide-stained nuclei. (e, f) U87MG and T98G cells were pretreated with the universal caspase inhibitor zVAD.fmk (60 mM) for 1 h, combined with 3 mM MG132 for 3 h and additionally treated for 24 h with TRAIL (black bars) or were pretreated with 3 mM MG132 for 2 h and additionally treated for 24 h with TRAIL (white bars), as indicated. All results are shown as mean of three independent triplicate experiments þ s.d.
Role of NF-jB in apoptosis of glioblastoma K La Ferla-Brühl et al (Sigma, Deisenhofen, Germany) was added to the filtrates. Thereafter, medium was removed from the U87MG or T98G cells and replaced with retrovirus containing PT67 cell supernatants. Culture plates were centrifuged at 1200 r.p.m. for 90 min at room temperature and incubated for another 4 h before the supernatants were replaced by conventional medium. Two days later, the retroviral transduction was confirmed by fluorescence microscopy or fluorescence-activated cell sorting (FACS) analysis. Infection efficiencies of U87MG or T98G cells ranged between 10 and 50%, depending on the retrovirus used. Forty-eight hours after infection U87MG cells were selected with 0.7 mg/ml and T98G cells with 0.35 mg/ml Zeocin for about 3 weeks.
Western blot
Western blotting was performed as previously described (Kasperczyk et al., 2005) . For IkBa detection, 50 mg of cytosolic proteins were loaded on 12% gels and transferred onto a nitrocellulose membrane. The membrane was incubated with either 1 mg/ml of IkBa (sc-371 Santa Cruz Biotechnology Inc.) polyclonal antibody or 0.5 mg/ml of a-tubulin (CP06, Calbiochem) monoclonal antibody. 
Viability assay
Cell viability was determined by incubation with the colorimetric substrate methylthiazol tetrezolium, using the 3-[4,5] dimethylthiazol-2,5-diphenyl tetrazolium bromide (MTT) assay according to manufacturer's instruction. Absorbance was measured using a plate reader (ELX 800, Bio-tek Instruments GmbH, Bad Friedrichshall, Germany).
Apoptosis assessment
Owing to its autofluorescence, apoptosis of cells treated with doxorubicin was assayed by Annexin V staining as described previously (Fulda et al., 1997) . Briefly, cells were incubated for 20 min in the darkness with Annexin-V-FITC (Annexin-V-Fluos, Roche Diagnostics, Mannheim, Germany) and then analysed by flow cytometry (FACScalibur, BD Biosciences, Heidelberg, Germany). Alternatively, apoptosis was determined by DNA fragmentation of propidium iodide-stained nuclei as described previously (Nicoletti et al., 1991) , with some modifications (Kasperczyk et al., 2005) . Briefly, cells were permeabilized and incubated in a propidium iodide solution (0.1% trinatriumcitrat-dihydrat, 0.4% Triton-X, 50 mg/ml propidium iodide, Sigma). Both methods were followed by flow cytometric analysis.
Immunostaining
Cells were seeded at a density of 5 Â 10 4 /well on eight-well glass culture slides (Falcon, BD Bioscience, Heidelberg, Germany). After appropriate incubation, cells were either stained with a 4,6-diamidino-2-phenylindole solution according to the manufacturer's instructions (Roche) or immunostained using the paraformaldehyde/Triton-X method, as described previously (Kasperczyk et al., 2005) . Antibodies used were: anti-p65 antibody (sc-372, Santa Cruz Biotechnology Inc.), antiphospho-Histone H2A.X (Ser139), clone JBW301 (Upstate cell signaling solutions, Charlottesville, VA, USA) and antirabbit FITC-conjugated secondary antibody (sc-3839, Santa Cruz Biotechnology Inc.). Staining for p65 was detected by confocal electron scanning microscopy (Leica DM IRB, Solms, Germany), whereas staining for phospho-H2A.X was visualized by fluorescence microscopy (Olympus Ax70, Hamburg, Germany).
Statistics
Statistical analysis was performed using the (two-population, independent) Student's t-test with the Origin software package (Microcal Software Inc., Northampton, MA, USA).
